Candriam S.C.A. Increases Stock Holdings in argenex SE $ARGX

Candriam S.C.A. grew its holdings in shares of argenex SE (NASDAQ:ARGX) by 10.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,567 shares of the company’s stock after purchasing an additional 4,287 shares during the period. Candriam S.C.A. owned about 0.07% of argenex worth $25,119,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in ARGX. IFP Advisors Inc grew its holdings in shares of argenex by 4.2% in the second quarter. IFP Advisors Inc now owns 666 shares of the company’s stock valued at $367,000 after purchasing an additional 27 shares in the last quarter. Keudell Morrison Wealth Management boosted its position in argenex by 5.5% in the 2nd quarter. Keudell Morrison Wealth Management now owns 534 shares of the company’s stock valued at $294,000 after buying an additional 28 shares during the period. Central Pacific Bank Trust Division grew its stake in shares of argenex by 2.4% in the second quarter. Central Pacific Bank Trust Division now owns 1,278 shares of the company’s stock worth $704,000 after acquiring an additional 30 shares in the last quarter. Janney Montgomery Scott LLC increased its position in shares of argenex by 2.6% during the second quarter. Janney Montgomery Scott LLC now owns 1,171 shares of the company’s stock worth $645,000 after acquiring an additional 30 shares during the period. Finally, Gilbert & Cook Inc. increased its position in shares of argenex by 2.4% during the second quarter. Gilbert & Cook Inc. now owns 1,345 shares of the company’s stock worth $741,000 after acquiring an additional 31 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Performance

ARGX opened at $891.73 on Friday. argenex SE has a one year low of $510.05 and a one year high of $907.47. The company has a market cap of $54.90 billion, a P/E ratio of 38.29, a PEG ratio of 0.91 and a beta of 0.45. The business’s 50-day simple moving average is $796.20 and its 200-day simple moving average is $670.33.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.37 by $0.03. argenex had a return on equity of 29.78% and a net margin of 41.58%.The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.07 billion. As a group, analysts predict that argenex SE will post 3.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research note on Wednesday, October 8th. Morgan Stanley lifted their price objective on argenex from $766.00 to $1,040.00 and gave the company an “overweight” rating in a research note on Wednesday, October 1st. HC Wainwright upped their target price on shares of argenex from $774.00 to $915.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Jefferies Financial Group set a $818.00 target price on shares of argenex and gave the company a “buy” rating in a report on Tuesday, August 26th. Finally, TD Cowen boosted their price target on shares of argenex from $800.00 to $1,146.00 and gave the stock a “buy” rating in a report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $879.28.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.